Back to Evidence
Primary experimental recordPositive observation

PMC10668963::ACT002846

CPS-3

Evidence text

Paper-level observation

Table 1: CPS-3 EC50/IC50 2.3 ± 0.4 µM (EMSA).
tableConfidence: medium

Assay observation

Activity
Antiviral
Subtype
General Antiviral
Measure
EC50
Comparator
=
Raw observation
2.3 ± 0.4 µM (EMSA)
Normalized measurement
=2.3 µM
Value minimum
1.9 µM
Value maximum
2.7 µM
Target
SARS-CoV-2
Assay method
Not reported by source
Sequence
Not reported by source
Standardization
insufficient information

Source publication

Unwinding the SARS-CoV-2 Ribosomal Frameshifting Pseudoknot with LNA and G-Clamp-Modified Phosphorothioate Oligonucleotides Inhibits Viral Replication

Biomolecules · 2023

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.